Giovanni D'Arena
Hematology and Stem Cell Transplantation Unit
IRCCS Centro di Riferimento Oncologico della Basilicata
Rionero in Vulture (PZ)
Sonya De Lorenzo
Hematology Unit, “Tortora” Hospital, Pagani (SA),
Maria Luigia Vigliotti
Hematology Unit, “San Sebastiano” Hospital, Caserta, Italy
Idanna Innocenti
Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy
Michele Cimminiello
Hematology Unit, “San Carlo” Hospital, Potenza, Italy;
Vittorio Simeon
Laboratory of Preclinical and Translational Research, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ);
Francesco Autore
Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy
Giuliana Farina
Hematology Unit, “San Sebastiano” Hospital, Caserta, Italy
Vincenzo Patella
Allergology Unit, “Santa Maria della Speranza” Hospital, Battipaglia (SA);
Vincenzo De Feo
Department of Pharmacology,
University of Salerno, Italy
Pellegrino Musto
Scientific Direction, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy
Luca Laurenti
Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy;
Keywords
rituximab, chronic lymphocytic leukemia, infusional adverse events
Abstract
A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.
[...]
Abstract